Suven Life Sciences has informed that it enclosed statement confirming that there were no deviation(s) or variation(s) in the use of proceeds, from the objects for which funds were raised through the preferential issue made by the Company, for the quarter ended 31st December, 2022.
The above information is a part of company’s filings submitted to BSE.